Jamie H. Cate
Biologist Faculty Scientist
Building: 955, Room 212C
Mail Stop: 5230
Phone: 510-541-7235
j-h-doudna-cate@berkeley.edu
https://sites.google.com/berkeley.edu/cate-lab/
Research Interests
Protein Synthesis Understanding how the ribosome makes proteins and how these proteins fold remains a major challenge in biology. The lab is interested in how the ribosome initiates protein synthesis in humans, a highly-regulated step important for human health. The lab is also exploring proteins as they emerge from the ribosome, and how they are targeted to their final destination. Using bacterial translation, we are exploring ways to engineer the ribosome to make polymers other than proteins. To determine the mechanisms underlying protein synthesis and its regulation, the lab uses a combination of cryo-electron microscopy, systems biology, biochemistry and biophysics.
Recent Publications
Related News
MBIB Leadership Changes Announced
Molecular Biophysics and Integrated Bioimaging (MBIB) Division Director Paul Adams has announced a number of changes in the Division leadership, effective October 1. Earlier this summer, Corie Ralston agreed to serve as the Interim Director of the Molecular Foundry's Biological Nanostructures Facility. She will step down as MBIB Division Deputy and remain as the Head of the Berkeley Center for Structural Biology (BCSB) at the Advanced Light Source (ALS).
Cate among Five Lab Scientists Named New AAAS Fellows
The new American Academy of Arts and Sciences (AAAS) fellows include Biosciences’ Jamie Cate from the Molecular Biophysics and Integrated Bioimaging Division. The other Berkeley Lab scientists honored are Christopher Chang (Chemical Sciences), Roger Falcone (ALS), Michael Witherell (Lab Director), and Katherine Yelick (Computing Sciences). AAAS fellowships recognize leading figures in academia, the arts, science, business, and government. Read more in the Berkeley Lab News Center.
New Drug Strategy: Target Ribosome to Halt Protein Production
The discovery of a chemical compound that halts the production of a small set of proteins while leaving general protein production untouched suggests a new drug search strategy: Find compounds that target undesired proteins before they are even made. In a paper appearing in the journal PLOS Biology, described the work of researchers at the University of California, Berkeley, and Pfizer Worldwide Research and Development. Faculty scientist Jamie Cate, Structural Biology Department Head in the Molecular Biophysics and Integrated Bioimaging Division, was a senior author of this study. Read the full story in Berkeley News.
